CJC-1295 vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Tirzepatide
Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | Tirzepatide |
|---|---|---|
| Dose Range | 1 mg–2 mg | 2.5 mg–15 mg |
| Frequency | Less than daily | Less than daily |
| Cycle Length | 8–12 weeks | 16–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Tirzepatide is based on the GIP peptide sequence with modifications enabling dual agonism at both GIP and GLP-1 receptors. GIP receptor activation enhances the effects of GLP-1 signaling: (1) potentiated insulin secretion beyond GLP-1 alone, (2) improved beta-cell function, (3) enhanced adipose tissue signaling that may improve fat metabolism, (4) potential protection against GLP-1-induced nausea via GIP receptor activity. The peptide has a C20 fatty diacid moiety enabling albumin binding and once-weekly dosing (half-life ~5 days). The dual mechanism explains the superior weight loss and glycemic outcomes compared to selective GLP-1 agonists. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | For weight management (Zepbound): start at 2.5 mg weekly for 4 weeks. Escalate to 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then 10 mg. May increase to 12.5 mg, then maximum 15 mg weekly. For type 2 diabetes (Mounjaro): same escalation schedule, maintenance at 5 mg, 10 mg, or 15 mg based on glycemic response. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Pre-filled single-dose pen — no reconstitution needed. Store refrigerated before first use; may be stored at room temperature (up to 86°F) for up to 21 days. Administer on the same day each week; may change the day if the last dose was given 3+ days prior. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Very common (>10%): nausea (up to 33%), diarrhea (up to 25%), decreased appetite, vomiting, constipation, dyspepsia, abdominal pain. Generally milder GI side effects than semaglutide, potentially due to GIP receptor co-activation. Common (1-10%): injection site reactions, fatigue, hypersensitivity reactions, GERD, hair loss, eructation. |
| Best For |
Key Differences
Unique to CJC-1295:
Unique to Tirzepatide:
Key Studies
CJC-1295
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.
Drug testing and analysis, 2019
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Drug testing and analysis, 2019
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Substance use & misuse, 2016
Tirzepatide
- Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
Cell metabolism, 2025
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
The New England journal of medicine, 2025
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
The New England journal of medicine, 2025
Ready to Learn More?
Looking for trusted sources?